Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1418 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Xiaoxu Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Dose-Response Relationship, Drug, Electrocardiography, Healthy Volunteers. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Cofrogliptin (HSK7653) is a long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes mellitus with a twice‐monthly dosing regimen. This study included 62 participants (48 without food effect, 14 with food effect) receiving single doses of HSK7653 (5, 10, 25, 50, 100, and 150 mg) or placebo. Pharmacokinetic samples were collected over 24 hours postdosing and sampling times are aligned with 12‐lead electrocardiograms (ECGs) which were derived from continuous ECG recordings. For the concentration‐QT interval corrected for heart rate (C‐QTc) analysis, we used linear mixed‐effects modeling to characterize the correlation between plasma concentrations of HSK7653 and the change from baseline in the QT interval which was corrected by Fridericia's formula (ΔQTcF). The result showed that a placebo‐corrected Fridericia corrected QT interval (ΔΔQTcF) prolongation higher than 10 milliseconds is unlikely at the mean maximum observed concentration (C max ) (411 ng/mL) associated with the recommended therapeutic doses (25 mg twice‐monthly), even at the highest supratherapeutic concentration (2425 ng/mL). Thus, HSK7653 does not significantly affect QT prolongation at either recommended doses or the highest supratherapeutic concentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science, Tianjin, China.
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China.
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, FL, USA.
- Haisco Pharmaceutical Group Co. Ltd., Chengdu, China.
Zitieren
APA
Wang, X., Liu, H., Cui, C., Niu, X., Li, H., Niu, S., Yan, P., Wu, N., Li, F., Wu, Q., Chen, K., Hu, B., & Liu, D. (2024). Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1418
Vancouver
Wang X, Liu H, Cui C, Niu X, Li H, Niu S, et al. Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1418
BibTeX
@article{Wang2024,
author = {Wang, Xiaoxu and Liu, Hongzhong and Cui, Cheng and Niu, Xiaoye and Li, Haiyan and Niu, Shu and Yan, Pangke and Wu, Nan and Li, Fangqiong and Wu, Qinghe and Chen, Kai and Hu, Bei and Liu, Dongyang},
title = {Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1418}
}
EUVIMED